The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.
Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.
This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.
We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America.
17:00-21:00 : WELCOME EVENING (BIO INNOVATION)
RIGHT Institute students present scientific posters, visit Bio Innovation and discover the regional biocluster.
8:30 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)
9:00 : WELCOME ADRESS AND INTRODUCTION (KURSAAL)
Dr. Sylvain Perruche, RIGHT Institute, Besançon, FR
Laurent Deschamps, PMT President, Besançon, FR
Representative of the President of Grand Besançon Métropole
Representative of the President of the Bourgogne Franche Comté Region
09:20-12:30 : SESSION #1 « UPCOMING INNOVATIVE THERAPIES »
Chairpersons : Dr. Christelle Monville, I-Stem, Evry and Dr. Sylvain Perruche, RIGHT Institute, Besançon, FR
09:20 : CELLS OR SECRETOME FOR THE TREATMENT OF HEART FAILURE ?
Prof. Dr. Philippe Menasché, INSERM U970 – Hôpital Européen Georges Pompidou, Paris, France
09:55 : IMMUNE SECRETOMES TARGETING AGE-ACQUIRED IMMUNE DECLINE
Dr. Hans Keirstead, Immunis, Irvine, USA
10:30 : BREAK – EXHIBITION HALL
11:15 : THE CLINICAL TRANSLATION OF ST266, A NOVEL AMNION CELL-DERIVED SECRETOME
Dr. Larry Brown, Noveome Biotherapeutics, Pittsburg, USA
11:45 : MACROPHAGE THERAPY FOR LIVER DISEASES, TITLE TO BE ANNOUNCED
Dr. Victor Dillard, Resolution Therapeutics, Edinburgh, UK
12:15-14:00 : LUNCH
13:00-14:30 : Exhibition Hall – B2B MEETINGS
14:00-14:30 : EFS SYMPOSIUM
Selected oral presentation from PhD students from the RIGHT Institute, Besançon, FR
14:30-18:00 : SESSION #2 “CAR TECHNOLOGY: FROM CAR-T TO CAR-NK”
Chairpersons: Dr. Marina Deschamps and Dr. Christophe Ferrand, RIGHT institute, Besançon, FR
14:30 :ALLOGENEIC CAR T-CELLS FOR ADOPTIVE CELL THERAPY
Dr. Mark Frattini, Cellectis, New-York, USA
15:00 : HIGH EFFECTIVENESS AND SAFETY OF ANTI-CD7 CAR T-CELL THERAPY IN TREATING RELAPSED OR REFRACTORY (R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)
Peihua (Peggy) Lu, MD, Lu Daopei Hospital and Beijing Lu Daopei Institute of Hematology, China
15:30 : ENABLING MANUFACTURING OF GENE-EDITING CELL THERAPIES
Dr. Mélanie Rietenbach, Miltenyi Biotech, Düsseldorf, Germany
16:00 : BREAK – EXHIBITION HALL
16:45 : DEVELOPMENT OF ALLOGENEIC CAR-T CELLS BASED ON T CELL PROGENITORS
Dr. Olivier Negre, Smart Immune, Paris, France
17:15 : NATURAL KILLER CELLS – ENGINEERED TO BEAT CANCER
Dr. Ralph Brandenberger, Nkarta Therapeutics, San Francisco, USA
18:00-19:30 : B2B MEETINGS OR VISIT OF BESANÇON
19:30 : COCKTAIL
(on registration only)
20:00 : EVENING RECEPTION
(on registration only)
8:30 : WELCOME COFFEE
08:30-09:15 : EXHIBITION HALL – B2B MEETINGS
09:15 – 12:00 : SESSION #3 “PATHWAYS FOR INNOVATIVE THERAPIES”
Chairpersons :Dr.Olivier Humbey, IQVIA, Dijon and Dr. Mathieu Guerriaud, CREDIMI, Dijon, FR
09:15 : PIPELINE ANALYSIS OF CELL AND GENE THERAPY PRODUCTS
Dr. Gavin Yirajen Vuddamalay, Mabdesign, Lyon, France
09:45 : EU SUPPORT AND INCENTIVES FOR INNOVATIVE DRUG DEVELOPMENT: OVERVIEW OF THE REGULATORY ADVICE TOOLBOX AND TREND ANALYSIS
Dr. Oriane Blanquie, European Medicines Agency, Amsterdam, Netherlands
10:15 : BREAK- EXHIBITION HALL
11:00 : HOW CAN CELL AND GENE THERAPIES OVERCOME CURRENT MARKET ACCESS CHALLENGES TO DELIVER ON THEIR PROMISE ?
Dr. Christopher Ball, IQVIA, London, UK
11:30 : DIGITAL SOLUTIONS TO SECURE YOUR BIOPROCESS: EFFICIENT FACILITY DESIGN AND ACCELERATED OPERATOR COMPETENCY – A RD-BIOTECH CASE STUDY
Kajsa Löwenhielm, Cytiva, Amersham, UK and Dr. Jean-Luc Schlick, RD-Biotech, Besançon, FR
12:00-14:00 : LUNCH
12:40-14:00 : Exhibition Hall – B2B MEETINGS
14:00-16:30 : SESSION #4 “CELL AND GENE THERAPIES”
Chairpersons :Dr. Fanny Delettre, EFS,andDr. Jean-Luc Schlick, RD-Biotech, Besançon, FR
14:00 : OVERVIEW OF CELL AND GENE THERAPY IN ANIMAL HEALTH
Dr. Michael Donabedian, Vetoquinol, Lure, France
14:30 : HOSPITAL EXEMPTION AS ALTERNATIVE TO SUCCEED IN ATMPS DEVELOPMENT : THE EXAMPLE OF THE ADICROHN PROJECT
Dr. Jérémy Magalon, AP-HM, Marseille, France
15:00 : BREAK – EXHIBITION HALL
15:30 : RETINAL PIGMENT EPITHELIAL CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS DISPOSED ON HUMAN AMNIOTIC MEMBRANE: AN UPDATE ON THE FRENCH RP CLINICAL TRIAL
Dr. Christelle Monville, I-Stem, Evry, France
16:00 : HUMAN CD34+ CELLS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
Dr. Ibon Garitaonandia, CellProthera, Mulhouse, France
16:30-16:45 : CONCLUSION END OF CONGRESS
Dr. Christophe Ferrand, RIGHT Institute, Besançon, FR
Renaud Gaudillière, PMT director, Besançon, FR
16:45–17:45 : B2B MEETINGS
16:45-18:00 : BEER PARTY
Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Dr Peihua (Peggy) LU – Lu Daopei Hospital & Institute of Hematology (Beijing, RPC), Dr Melanie RIETENBACH – Miltenyi Biotec ( Düsseldorf, DE), Dr Oriane BLANQUIE, EMA ( Amsterdam, NL), Prof. Dr. Philippe Menasché, Service de chirurgie cardiovasculaire – Hôpital Européen Georges Pompidou,( Paris, FR), Dr Victor Dillard, Resolution Therapeutics, (Edinburgh, UK), Dr Christelle Monville, I-Stem (Evry, FR), Dr Hans Keirstead, Immunis (Irvine, USA), Dr Mark Frattini, Cellectis, (New-York, USA), Dr Juan R. Rodriguez-Madoz, Center for Applied Medical Research (CIMA),(University of Navarra, Spain), Dr Ralph Brandenberger, Nkarta Therapeutics, (San Francisco, USA), Dr Gavin Yirajen Vuddamalay, Mabdesign, (Lyon, FR), Dr Jean-Luc Schlick, RD-Biotech, (Besançon, FR), Dr Michael Donabedian, Vetoquinol, (Lure, FR), Dr Jérémy Magalon, AP-HM, (Marseille, FR), Dr Ibon Garitaonandia, CellProthera, (Mulhouse, FR)
Fanny Delettre, PharmD, Ph.D ; Director of Biology, Therapy and Diagnosis Department in « Etablissement Français du sang » Bourgogne Franche Comté (EFS BFC) and researcher in UMR Right. During her Ph.D and her postdoc in immunology laboratory in Besançon,...
En savoir +Kajsa Löwenhielm loves to untie knots. Currently, she’s applying her problem-solving mindset to find efficient solutions to the talent gap in the biopharma industry. With a master’s degree in medical science, Kajsa embraces the challenge of making the complex clear...
En savoir +Gavin holds a PhD in Immunology and Infectious Diseases from the University of Toulouse III (Paul Sabatier). He has previous experience as preclinical laboratory manager, university lecturer and consulting advisor to research funding agencies. At MabDesign, Gavin heads the business...
En savoir +Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.
En savoir +Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...
En savoir +European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...
En savoir +Dr. Ibon Garitaonandia is the Chief Scientific Officer at CellProthera, a French clinical stage biotechnology company developing stem cell based therapies for cardiovascular and ischemic indications. He is conducting a Phase 2 study in post-acute myocardial infarction (NCT02669810) and preclinical...
En savoir +Dr Christopher Ball is a biotech client partner at IQVIA and a member of IQVIA’s cell and gene therapy commercialization team. He works strategically with biotech companies to help them get their therapies to more patients faster. Chris has over...
En savoir +Dr. Larry Brown currently serves as Chief Scientific Officer and Executive Vice President of Research at Noveome Biotherapeutics Inc. in Pittsburgh, PA, United States. He is leading the translation of the ST266 secretome therapeutic from proof of principle into the...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +A doctor in biology, the Bisontinental Inserm researcher worked for nearly ten years within Inserm's Joint Research Unit 1098 - hosted by the Etablissement français du sang Bourgogne-Franche-Comté, in Besançon - in the development of therapeutic approaches to control the...
En savoir +Olivier graduated from ENSTBB engineering school in Bordeaux and earned a doctorate degree in cell and molecular biology from Paris Diderot University. He developed his expertise in preclinical research and translational science through more than 20 years of experience in...
En savoir +Jean-Luc Schlick holds a PhD in Biochemistry and Molecular Biology from Sciences University of Franche-Comté (Besancon, Fr). He is a co-founder of RD-BIOTECH SAS founded in 2002 with Philippe Dulieu and Jean-François Musard. In 2002, he was head of the...
En savoir +Mathieu Guerriaud is a Doctor of Pharmacy (PharmD) and a Doctor of Science (PhD). He is an associate professor in pharmaceutical law, teaching at the Faculty of Health Sciences while working as a researcher in a law laboratory: the CREDIMI....
En savoir +Melanie Rietenbach is a Global Product Manager for the Immunotherapy portfolio at Miltenyi Biotec. During the last 3 years, she has been working together with the R&D and Clinical Development Team in order to advance the development of tools to...
En savoir +Christelle Monville obtained a PhD in Neurobiology in 2000. She is currently professor at Paris Saclay-Evry’s University and team leader at the Istem lab (France). The objectives of her group are (1) to develop pre-clinical studies required for the development...
En savoir +Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that led the development of a treatment that restored movement and sensory function to people with quadriplegic spinal cord injury, and a treatment for cancer that has saved...
En savoir +Dr Philippe Menasché is a cardiac surgeon at the Georges Pompidou European Hospital, Professor of Thoracic and Cardiovascular Surgery at the Paris-Cité University, and is in charge of an INSERM team dedicated to cell therapy for heart failure. After the...
En savoir +After completing my pharmacy studies in Paris, France, I did a PhD in Neuroscience at the University Medical Center of Mainz, Germany (2013-2017), followed by a postdoc at the German Center for Neurodegenerative Diseases in Bonn, Germany (2017 – 2018)....
En savoir +Dr. Brandenberger is the Chief Technical Officer and oversees technical operations, including process and analytical development, supply chain, manufacturing, and quality for Nkarta’s engineered NK cell therapy candidates. He has more than 20 years of experience in process and analytical...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice President of Clinical Sciences where he has been responsible for Cellectis’ clinical leadership including the clinical development...
En savoir +